Similar articles

• Non-heparin glycosaminoglycan-derived drugs: a biochemical and pharmacologic perspective.

  Walenga JM, Hoppensteadt D, Fareed J. Walenga JM, et al. Semin Thromb Hemost. 1991;17 Suppl 2:137-42. Semin Thromb Hemost. 1991. PMID: 1835134 Review.
• Glycosaminoglycans from Ateroid and bovine duodenal mucosa and pancreas.

  Seethanathan P, Dalferes E Jr, Radhakrishnamurthy BS, Victor R, Berenson GS. Seethanathan P, et al. Mol Cell Biochem. 1975 Sep 30;8(3):177-83. doi: 10.1007/BF01792768. Mol Cell Biochem. 1975. PMID: 52831
• Sulodexide: a renewed interest in this glycosaminoglycan.

  Lauver DA, Lucchesi BR. Lauver DA, et al. Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):214-26. doi: 10.1111/j.1527-3466.2006.00214.x. Cardiovasc Drug Rev. 2006. PMID: 17214598 Review.
• [The problem of an antilipemic synergism between the action of nicotinic acid and the sulphated polyanion SP54 (author's transl)].

  Levy H. Levy H. Med Klin. 1974 Sep 6;69(36):1441-7. Med Klin. 1974. PMID: 4280008 Clinical Trial. German. No abstract available.
• Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.

  Hoppensteadt D, Racanelli A, Walenga JM, Fareed J. Hoppensteadt D, et al. Semin Thromb Hemost. 1989 Oct;15(4):378-85. doi: 10.1055/s-2007-1002734. Semin Thromb Hemost. 1989. PMID: 2530633 No abstract available.